Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
FUS
REST API REST API
Homo sapiens
FUS is differentially expressed in 353 experiments: 161 organism parts: liver, salivary gland, ... (159 more);, 233 disease states: normal, breast carcinoma, ... (231 more);, 105 cell types 417 cell lines 45 compound treatments and 84 other conditions.
Synonyms FUS1, ALS6, hnRNP-P2, TLS
Orthologs Fus (Rattus norvegicus)   Fus (Mus musculus)   D3ZSJ6_RAT (Rattus norvegicus)   FUS (Bos taurus)   D3ZH93_RAT (Rattus norvegicus)   GAR1 (Saccharomyces cerevisiae)   fus (Danio rerio)   caz (Drosophila melanogaster)   CG14718 (Drosophila melanogaster)   fus (Xenopus laevis)   FUS (Canis familiaris)   (Compare orthologs)
Gene Ontology Term RNA splicing, DNA binding, protein binding, cytoplasm, intracellular, metal ion binding, nucleic acid binding, nucleus, cell death, nucleotide binding, nuclear mRNA splicing, via spliceosome, nucleoplasm, RNA binding, zinc ion binding, gene expression
InterPro Term Znf_RanBP2, RRM_dom
UniProt Accession P35637, Q6IBQ5, A6NMX6, B4DR70, E7EUX0
Gene-Disease Assocation HISTIOCYTOMA, ANGIOMATOID FIBROUS, AMYOTROPHIC LATERAL SCLEROSIS 6, WITH OR WITHOUT FRONTOTEMPORAL DEMENTIA;
Search EB-eye ENSG00000089280
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-GEOD-22541, E-GEOD-6573, E-GEOD-1577, ... (33 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-GEOD-18005, E-GEOD-19397, ... (38 experiments)

Factor Value U/D Experiments
MCF-7
4
E-GEOD-19639, E-GEOD-20081, E-GEOD-5823, E-GEOD-3529
MDA-MB-231
3
E-GEOD-5823, E-TABM-420, E-MTAB-62
HepG2
2
E-GEOD-21154, E-MTAB-37
CCRFCEM
2
E-GEOD-24147, E-MTAB-37
HL-60
2
E-MTAB-37, E-GEOD-24147
MCF7
2
E-MTAB-37, E-GEOD-5258
411 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-21668, E-GEOD-3920, E-MEXP-750, E-GEOD-20677, ... (51 experiments)

Factor Value U/D Experiments
mononuclear cell
2
E-GEOD-7307, E-GEOD-6053
fibroblast
2
E-GEOD-26672, E-GEOD-3920
721 B lymphoblast
2
E-AFMX-5, E-TABM-145
CD34+
2
E-AFMX-5, E-TABM-145
mononuclear
2
E-GEOD-26672, E-GEOD-13987
monocyte
2
3
E-MEXP-2019, E-GEOD-7307, E-MEXP-583, E-GEOD-5099, E-GEOD-22373 ... (5 experiments)
99 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-GEOD-1577, E-MEXP-2280, ... (66 experiments)

Factor Value U/D Experiments
lung adenocarcinoma
4
E-MTAB-37, E-MTAB-62, E-GEOD-2514, E-MEXP-231
colon carcinoma
3
E-MTAB-62, E-MTAB-37, E-GEOD-3726
glioblastoma
1
3
E-MTAB-37, E-MTAB-62, E-GEOD-4290, E-GEOD-6014
cervical carcinoma
1
3
E-MTAB-62, E-MTAB-37, E-GEOD-5823, E-MEXP-1331
chronic lymphocytic leukemia
2
E-GEOD-2466, E-GEOD-6691
Emery-Dreifuss muscular dystrophy
2
E-MTAB-62, E-GEOD-3307
227 more value(s).


Compound treatment

studied in E-GEOD-5741, E-TABM-782, E-GEOD-5824, E-MEXP-1958, E-MEXP-2590, ... (30 experiments)

Factor Value U/D Experiments
none
3
7
E-TABM-782, E-GEOD-5824, E-MEXP-1601, E-GEOD-2803, E-MEXP-1958, ... (10 experiments)
control
2
E-GEOD-3284, E-GEOD-4006
ethanol
2
E-MEXP-2241, E-GEOD-3113
glutamine
2
E-MEXP-1335, E-MEXP-941
placebo
2
E-MEXP-1335, E-MEXP-1327
anti-CD3 antibody (clone:OKT3)
1
E-MEXP-1601
39 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
1
E-GEOD-19519
thapsigargin
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519


Biosource provider
studied in E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-22097, E-GEOD-19420, E-GEOD-19743, E-GEOD-7967, E-TABM-125, ... (8 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-19348, E-GEOD-1140, ... (12 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-2171, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-GEOD-1614, E-GEOD-1638, E-GEOD-20033, E-GEOD-3140, ... (8 experiments)

Dfs follow up
studied in E-GEOD-22541

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-89, E-GEOD-1323, E-GEOD-19743, E-GEOD-7788, E-GEOD-22541, ... (10 experiments)

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-GEOD-7011, E-MTAB-73, E-MEXP-1482, E-GEOD-7578, ... (9 experiments)

Genotype
studied in E-TABM-1029, E-GEOD-2466, E-GEOD-17476, E-GEOD-22593, E-GEOD-18736, ... (12 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-GEOD-7011, E-MEXP-2657, E-GEOD-10315, E-TABM-440, ... (13 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-302, E-TABM-276, E-GEOD-20194, E-GEOD-16716 ... (5 experiments)

Individual
studied in E-TABM-325, E-MTAB-197, E-MEXP-2069, E-GEOD-1926, E-GEOD-3720, ... (45 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-12108, E-MEXP-561, E-GEOD-6802, E-GEOD-512, ... (6 experiments)

Initial distant metastases
studied in E-GEOD-22541

Injury
studied in E-GEOD-19743

Irradiate
studied in E-MEXP-2177

Karyotype
studied in E-GEOD-7214

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Localisation of metastases
studied in E-GEOD-22541

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

P53 ihc
studied in E-GEOD-21653

Performer
studied in E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-19703, E-GEOD-6434, E-GEOD-1657, E-GEOD-1460, E-GEOD-2487, ... (7 experiments)

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, ... (6 experiments)

pt
studied in E-GEOD-21653

Replicate
studied in E-GEOD-18791, E-GEOD-10896

RNAi
studied in E-MEXP-2115, E-GEOD-12438, E-MEXP-101, E-GEOD-3697, E-MEXP-1857, ... (6 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-17400, E-GEOD-18995

Sex
studied in E-GEOD-19743, E-GEOD-2466, E-GEOD-7307

Sirna
studied in E-GEOD-21575, E-GEOD-21574

Stimulation
studied in E-GEOD-4883, E-GEOD-20114, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-MEXP-1996, E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926, E-TABM-276

Tissue
studied in E-GEOD-30573

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-21909, E-GEOD-19246, E-GEOD-13818, E-GEOD-19815, E-GEOD-15799, ... (6 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-89, E-GEOD-4271, E-GEOD-22541

Vehicle
studied in E-GEOD-5258

Processing time: 0.27 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM